Evidence map›Paper›PMID 29441205›Full record

ArticleBiomarker research2018

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice.

Vicki Xie, Daochen Tong, Craig T Wallington-Beddoe, Ken F Bradstock, Linda J Bendall

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Vicki Xie1Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Daochen Tong1Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Craig T Wallington-Beddoe1Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Ken F Bradstock2Haematology Department, Westmead Hospital, Westmead, NSW Australia.
Linda J Bendall1Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.ORCID 0000-0002-7174-3421
The University of Sydney · AUSouth Australia Pathology · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL).

methodsIn this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF.

resultsMice lacking ARF and SphK2 had a significantly reduced incidence of ALL compared mice with wild type SphK2.

conclusionsThese results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1.

Indexed as

Acute lymphoblastic leukemiaMouse modelsSphingosine kinase 2

Identifiers

PMID29441205
PMCPMC5800079
OpenAlexW2786628950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.